These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 9669503)

  • 1. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
    Liao CH; Tzeng CC; Teng CM
    Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases.
    Wu CC; Wang WY; Kuo RY; Chang FR; Wu YC
    Eur J Pharmacol; 2004 Jan; 483(2-3):187-94. PubMed ID: 14729106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
    Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
    Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
    Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
    Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YC-1, a novel activator of platelet guanylate cyclase.
    Ko FN; Wu CC; Kuo SC; Lee FY; Teng CM
    Blood; 1994 Dec; 84(12):4226-33. PubMed ID: 7527671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
    Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
    Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of inhibition of platelet aggregation by HCL-31D.
    Chou TC; Li CY; Lee AR; Wu TM
    Eur J Pharmacol; 2000 Jan; 387(2):125-31. PubMed ID: 10650152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.
    Hagiwara M; Endo T; Kanayama T; Hidaka H
    J Pharmacol Exp Ther; 1984 Feb; 228(2):467-71. PubMed ID: 6141286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotides and platelet aggregation. Effect of aggregating agents on the activity of cyclic nucleotide-metabolizing enzymes.
    Barber AJ
    Biochim Biophys Acta; 1976 Sep; 444(2):579-95. PubMed ID: 9149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet effect of marchantinquinone, isolated from Reboulia hemisphaerica, in rabbit washed platelets.
    Liao CH; Ko FN; Wu CL; Teng CM
    J Pharm Pharmacol; 2000 Mar; 52(3):353-9. PubMed ID: 10757426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepacrine-induced elevation of cyclic GMP levels and acceleration of reversal of ADP-induced aggregation in washed rabbit platelets.
    Matsuoka I; Suzuki T
    J Cyclic Nucleotide Protein Phosphor Res; 1983; 9(4-5):341-53. PubMed ID: 6147364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets.
    Yu SM; Chen CC; Ko FN; Huang YL; Huang TF; Teng CM
    Biochem Pharmacol; 1992 Jan; 43(2):323-9. PubMed ID: 1310852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.
    Hirose R; Okumura H; Yoshimatsu A; Irie J; Onoda Y; Nomoto Y; Takai H; Ohno T; Ichimura M
    Eur J Pharmacol; 2001 Nov; 431(1):17-24. PubMed ID: 11716838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet effect of demethyldiisoeugenol.
    Liao CH; Ko FN; Kuo YH; Teng CM
    Can J Physiol Pharmacol; 1996 Oct; 74(10):1111-6. PubMed ID: 9022830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta.
    Yu SM; Kuo SC
    Br J Pharmacol; 1995 Apr; 114(8):1587-94. PubMed ID: 7599926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
    Azuma H; Takashima Y; Ishikawa M; Yamakado T
    Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of PP1D-1, a synthetic antiplatelet compound, on rabbit platelets.
    Liao CH; Ko FN; Kuo SC; Teng CM
    Jpn J Pharmacol; 1998 Feb; 76(2):141-8. PubMed ID: 9541276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of cyclic AMP and cyclic GMP in Morris hepatomas and liver.
    Hickie RA
    Adv Exp Med Biol; 1977 May 22-24; 92():451-88. PubMed ID: 24988
    [No Abstract]   [Full Text] [Related]  

  • 20. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin.
    Chou TC; Lin YF; Wu WC; Chu KM
    Br J Pharmacol; 2008 Mar; 153(6):1281-7. PubMed ID: 18264124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.